Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00899197 · ClinicalTrials.gov registry record
Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- 2
- Enrollment target
NCT00899197: Clinical Trial study, sponsored by Wake Forest University Health Sciences.
NCT00899197 is a clinical trial that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00899197 was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of blood from patients with breast cancer in the laboratory may help doctors identify and learn more about biomarkers related to tamoxifen resistance. PURPOSE: This laboratory study is looking at tamoxifen resistance in women with stage I, stage II, stage IIIA, or stage IIIB breast cancer.
Interventions
- GENETIC gene expression analysis
- GENETIC protein expression analysis
- OTHER laboratory biomarker analysis
- OTHER immunoenzyme technique
- DRUG tamoxifen citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2007-05 |
| Est. Completion | 2012-06 |
Why NCT00899197 stopped before completion
NCT00899197 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.
The record links to 0 conditions, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00899197 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00899197 about?
NCT00899197 is a clinical study titled "Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer". RATIONALE: Studying samples of blood from patients with breast cancer in the laboratory may help doctors identify and learn more about biomarkers related to tamoxifen resistance. PURPOSE: This laboratory study is looking at tamoxifen resistance in women with stage I, stage II, stage IIIA, or stage ...
What is the current status of trial NCT00899197?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2007-05. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00899197?
The interventions under investigation include: gene expression analysis (GENETIC), protein expression analysis (GENETIC), laboratory biomarker analysis (OTHER), immunoenzyme technique (OTHER), tamoxifen citrate (DRUG).
Who is sponsoring clinical trial NCT00899197?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia